155 related articles for article (PubMed ID: 35791353)
1. Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue Distribution.
Ke R; Martinez PP; Smith RL; Gibson LL; Achenbach CJ; McFall S; Qi C; Jacob J; Dembele E; Bundy C; Simons LM; Ozer EA; Hultquist JF; Lorenzo-Redondo R; Opdycke AK; Hawkins C; Murphy RL; Mirza A; Conte M; Gallagher N; Luo CH; Jarrett J; Conte A; Zhou R; Farjo M; Rendon G; Fields CJ; Wang L; Fredrickson R; Baughman ME; Chiu KK; Choi H; Scardina KR; Owens AN; Broach J; Barton B; Lazar P; Robinson ML; Mostafa HH; Manabe YC; Pekosz A; McManus DD; Brooke CB
Open Forum Infect Dis; 2022 Jul; 9(7):ofac192. PubMed ID: 35791353
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution.
Ke R; Martinez PP; Smith RL; Gibson LL; Achenbach CJ; McFall S; Qi C; Jacob J; Dembele E; Bundy C; Simons LM; Ozer EA; Hultquist JF; Lorenzo-Redondo R; Opdycke AK; Hawkins C; Murphy RL; Mirza A; Conte M; Gallagher N; Luo CH; Jarrett J; Conte A; Zhou R; Farjo M; Rendon G; Fields CJ; Wang L; Fredrickson R; Baughman ME; Chiu KK; Choi H; Scardina KR; Owens AN; Broach J; Barton B; Lazar P; Robinson ML; Mostafa HH; Manabe YC; Pekosz A; McManus DD; Brooke CB
medRxiv; 2021 Sep; ():. PubMed ID: 34494028
[TBL] [Abstract][Full Text] [Related]
3. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals.
Jung J; Kim JY; Park H; Park S; Lim JS; Lim SY; Bae S; Lim YJ; Kim EO; Kim J; Park MS; Kim SH
JAMA Netw Open; 2022 May; 5(5):e2213606. PubMed ID: 35608859
[TBL] [Abstract][Full Text] [Related]
4. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
[TBL] [Abstract][Full Text] [Related]
5. Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study.
Garcia-Knight M; Anglin K; Tassetto M; Lu S; Zhang A; Goldberg SA; Catching A; Davidson MC; Shak JR; Romero M; Pineda-Ramirez J; Diaz-Sanchez R; Rugart P; Donohue K; Massachi J; Sans HM; Djomaleu M; Mathur S; Servellita V; McIlwain D; Gaudiliere B; Chen J; Martinez EO; Tavs JM; Bronstone G; Weiss J; Watson JT; Briggs-Hagen M; Abedi GR; Rutherford GW; Deeks SG; Chiu C; Saydah S; Peluso MJ; Midgley CM; Martin JN; Andino R; Kelly JD
PLoS Pathog; 2022 Sep; 18(9):e1010802. PubMed ID: 36095030
[TBL] [Abstract][Full Text] [Related]
6. Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience.
Strickler SS; Esper A; Wells L; Wood A; Frediani JK; Nehl E; Waggoner JJ; Rebolledo PA; Levy JM; Figueroa J; Ramachandra T; Lam W; Martin GS
Front Med (Lausanne); 2022; 9():1031083. PubMed ID: 36507539
[TBL] [Abstract][Full Text] [Related]
7. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
medRxiv; 2022 Jan; ():. PubMed ID: 35118480
[TBL] [Abstract][Full Text] [Related]
8. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.
Butt AA; Yan P; Shaikh OS; Mayr FB; Omer SB
Clin Infect Dis; 2022 Aug; 75(1):e849-e856. PubMed ID: 34893812
[TBL] [Abstract][Full Text] [Related]
9. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
[TBL] [Abstract][Full Text] [Related]
11. Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
Salvatore PP; Lee CC; Sleweon S; McCormick DW; Nicolae L; Knipe K; Dixon T; Banta R; Ogle I; Young C; Dusseau C; Salmonson S; Ogden C; Godwin E; Ballom T; Rhodes T; Wynn NT; David E; Bessey TK; Kim G; Suppiah S; Tamin A; Harcourt JL; Sheth M; Lowe L; Browne H; Tate JE; Kirking HL; Hagan LM
Vaccine; 2023 Mar; 41(11):1808-1818. PubMed ID: 36572604
[TBL] [Abstract][Full Text] [Related]
12. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
[TBL] [Abstract][Full Text] [Related]
13. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
Puhach O; Adea K; Hulo N; Sattonnet P; Genecand C; Iten A; Jacquérioz F; Kaiser L; Vetter P; Eckerle I; Meyer B
Nat Med; 2022 Jul; 28(7):1491-1500. PubMed ID: 35395151
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
[TBL] [Abstract][Full Text] [Related]
15. Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals.
Huai Luo C; Paul Morris C; Sachithanandham J; Amadi A; Gaston DC; Li M; Swanson NJ; Schwartz M; Klein EY; Pekosz A; Mostafa HH
Clin Infect Dis; 2022 Aug; 75(1):e715-e725. PubMed ID: 34922338
[TBL] [Abstract][Full Text] [Related]
16. Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals.
Caserta LC; Martins M; Cronk B; Anderson R; Eldridge H; Gallow D; Kruppa F; Plocharczyk E; Diel DG
Microbiol Spectr; 2022 Oct; 10(5):e0056322. PubMed ID: 36165775
[TBL] [Abstract][Full Text] [Related]
17. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
[TBL] [Abstract][Full Text] [Related]
18. Active viral shedding in a vaccinated hospitalized patient infected with the delta variant (B.1.617.2) of SARS-CoV-2 and challenges of de-isolation.
Alshukairi AN; Al-Omari A; Al-Tawfiq JA; El-Kafrawy SA; El-Daly MM; Hassan AM; Faizo AA; Alandijany TA; Dada A; Saeedi MF; Alhamlan FS; Al Hroub MK; Qushmaq I; Azhar EI
J Infect Public Health; 2022 Jun; 15(6):628-630. PubMed ID: 35576779
[TBL] [Abstract][Full Text] [Related]
19. Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type.
Dingemans J; van der Veer BMJW; Gorgels KMF; Hackert V; den Heijer CDJ; Hoebe CJPA; Savelkoul PHM; van Alphen LB
Front Microbiol; 2022; 13():1027271. PubMed ID: 36504818
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
